We are live on ! Find out more
OTLK icon

Outlook Therapeutics
OTLK

82 hedge funds and large institutions have $29.7M invested in Outlook Therapeutics in 2023 Q1 according to their latest regulatory filings, with 14 funds opening new positions, 34 increasing their positions, 8 reducing their positions, and 7 closing their positions.

New
Increased
Maintained
Reduced
Closed

325% more repeat investments, than reductions

Existing positions increased: 34 | Existing positions reduced: 8

100% more first-time investments, than exits

New positions opened: 14 | Existing positions closed: 7

9% more funds holding

Funds holding: 75 → 82 (+7)

0% more capital invested

Capital invested by funds: $29.6M → $29.7M (+$125K)

0.07% less ownership

Funds ownership: 0.61% → 0.53% (-0.07%)

Holders
82
Holders Change
+7
Holders Change %
+9.33%
% of All Funds
1.31%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
14
Increased
34
Reduced
8
Closed
7
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
BlackRock
BlackRock
New York
+$1.14M
2
Geode Capital Management
Geode Capital Management
Massachusetts
+$532K
3
Vanguard Group
Vanguard Group
Pennsylvania
+$389K
4
Millennium Management
Millennium Management
New York
+$382K
5
Northern Trust
Northern Trust
Illinois
+$287K

Top Sellers

Rank Fund Capital Flow
1
ACM
Altium Capital Management
New York
-$3.59M
2
GCP
GSA Capital Partners
United Kingdom
-$201K
3
Goldman Sachs
Goldman Sachs
New York
-$130K
4
VF
Vista Finance
Missouri
-$67.1K
5
Two Sigma Advisers
Two Sigma Advisers
New York
-$53.7K
Name Holding Trade Value Shares
Change 		Change in
Stake
BlackRock
1
BlackRock
New York
$8.79M +$1.14M +51,071 +14%
Vanguard Group
2
Vanguard Group
Pennsylvania
$6.55M +$389K +17,394 +6%
Geode Capital Management
3
Geode Capital Management
Massachusetts
$2.77M +$532K +23,774 +23%
State Street
4
State Street
Massachusetts
$2.2M +$112K +5,019 +5%
LA
5
LVW Advisors
New York
$1.89M – – –
Northern Trust
6
Northern Trust
Illinois
$1.31M +$287K +12,809 +27%
N
7
Nuveen
North Carolina
$933K +$55.1K +2,464 +6%
Millennium Management
8
Millennium Management
New York
$562K +$382K +17,064 +196%
Bank of New York Mellon
9
Bank of New York Mellon
New York
$460K +$71.6K +3,199 +18%
Charles Schwab
10
Charles Schwab
California
$449K +$92.9K +4,151 +25%
VF
11
Vista Finance
Missouri
$237K -$67.1K -2,999 -22%
LNC
12
Lincoln National Corp
Pennsylvania
$212K – – –
RhumbLine Advisers
13
RhumbLine Advisers
Massachusetts
$194K +$36.7K +1,642 +23%
Wells Fargo
14
Wells Fargo
California
$184K +$33.2K +1,483 +21%
Morgan Stanley
15
Morgan Stanley
New York
$175K +$73.3K +3,278 +69%
FMC
16
First Merchants Corp
Indiana
$161K – – –
Bank of America
17
Bank of America
North Carolina
$139K -$23.4K -1,045 -14%
JP Morgan Chase
18
JP Morgan Chase
New York
$129K +$57.5K +2,571 +76%
AA
19
Ancora Advisors
Ohio
$118K – – –
LPL Financial
20
LPL Financial
California
$110K – – –
Deutsche Bank
21
Deutsche Bank
Germany
$108K +$53.8K +2,405 +94%
GCP
22
GSA Capital Partners
United Kingdom
$107K -$201K -8,997 -65%
Citadel Advisors
23
Citadel Advisors
Florida
$98.8K +$55.3K +2,472 +120%
Susquehanna International Group
24
Susquehanna International Group
Pennsylvania
$96.3K +$74.8K +3,345 +311%
MIM
25
MetLife Investment Management
New Jersey
$90.9K +$93.3K +4,172 New
1
2 3 4

OTLK Hedge Fund Activity: Q1 2023 in Review

82 of the 6,275 institutional investors tracked by Wall St. Rank reported a position in Outlook Therapeutics (OTLK) for Q1 2023, worth a combined $29.7M — up 0.42% from $29.6M a quarter earlier.

Buyers outnumbered sellers: 14 funds opened new OTLK positions and 7 closed out — a net gain of 7 holders — while 34 added to existing stakes and 8 trimmed.

The largest buyer was BlackRock, adding an estimated $1.14M. The largest seller was Altium Capital Management, exiting entirely with an estimated $3.59M sold.

  • 82 institutional investors held Outlook Therapeutics (OTLK) as of Q1 2023, up from 75 in Q4 2022.
  • Funds reported $29.7M of Outlook Therapeutics stock for Q1 2023, up 0.42% quarter-over-quarter.
  • 14 funds opened new Outlook Therapeutics positions in Q1 2023 and 7 closed out, a net change of +7 holders.
  • The largest Outlook Therapeutics buyer in Q1 2023 was BlackRock, an estimated $1.14M added.
  • The largest Outlook Therapeutics seller in Q1 2023 was Altium Capital Management, an estimated $3.59M sold.

Based on aggregated 13F filings for Q1 2023.